Physician profile
Edward J Holland
NPI 1720021199
$677,841.19
in general payments reported to CMS, 2019-2025
30 companies · $135K in 2025
The $135K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156K · 2020: $213K · 2021: $100K · 2022: $73K · 2023: $441 · 2024: $667 · 2025: $135K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $133K · Food and Beverage: $2,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $133,392.00 |
| Food and Beverage | $2,264.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $199,055.40 | 2019-2022 | |
| Alcon Vision LLC | $159,163.29 | 2019-2025 | Rocklatan, Eysuvis, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $123,552.79 | 2019-2024 | Veritas Vision System |
| Glaukos Corporation | $84,804.85 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Research LLC | $29,581.07 | 2019-2023 | Acrysof Iq Vivity |
| Novartis Pharmaceuticals Corporation | $28,572.18 | 2019-2023 | |
| Sight Sciences, INC. | $12,689.18 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $9,888.74 | 2019-2021 | |
| Dompe US, INC. | $6,555.23 | 2019-2025 | Oxervate |
| Ocular Therapeutix, INC. | $5,268.78 | 2020 | |
| Aerie Pharmaceuticals, INC. | $5,193.85 | 2019-2021 | |
| Merck Kgaa | $4,270.00 | 2020-2021 | |
| Oyster Point Pharma, INC. | $2,523.98 | 2022-2023 | Tyrvaya |
| Shire North American Group INC | $2,081.83 | 2019 | |
| Eyevance Pharmaceuticals LLC | $1,034.26 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $1,016.84 | 2019 | |
| Allergan, INC. | $755.95 | 2019-2021 | |
| Tearlab Corp | $547.06 | 2019-2021 | |
| Harrow Eye, LLC | $406.81 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $247.10 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $131.05 | 2022-2025 | Vyzulta |
| Biotissue Holdings INC. | $128.43 | 2022-2023 | |
| Abbvie INC. | $108.18 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $78.90 | 2022-2023 | Cequa |
| Regeneron Healthcare Solutions, INC. | $59.47 | 2024-2025 | Eylea Hd |
| Alimera Sciences, INC. | $58.45 | 2022-2024 | Yutiq, Iluvien |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $50.85 | 2020-2021 | |
| Coherus Oncology, INC. | $16.67 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$75,990.60 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Holland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.